Stephane Bancel, Chief Executive Officer at Moderna, Inc. (MRNA), sold 113,500 shares at $130.27 ($14.9M) on 2023-04-26, disclosed to the SEC on 2023-04-28.
Scheduled sale ($14.9M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $130.27 | 7,600 | $990K | 6.6% |
| 2 | $130.27 | 7,600 | $990K | 6.6% |
| 3 | $131.10 | 16,898 | $2.2M | 14.9% |
| 4 | $131.10 | 16,898 | $2.2M | 14.9% |
| 5 | $132.55 | 9,002 | $1.2M | 8.0% |
| 6 | $132.55 | 9,002 |
| $1.2M |
| 8.0% |
| 7 | $133.93 | 6,500 | $871K | 5.8% |
| 8 | $130.41 | 29,600 | $3.9M | 25.9% |
| 9 | $131.16 | 9,900 | $1.3M | 8.7% |
| 10 | $131.90 | 500 | $66K | 0.4% |
| Total | $131.21 avg | 113,500 | $14.9M | 100% |
| Filing → |
| MRNA | SELL | 2024-02-16 | $4.7M | — | Filing → |
| MRNA | SELL | 2023-06-30 | $6.6M | — | Filing → |
| MRNA | SELL | 2023-06-23 | $19.3M | — | Filing → |